{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Taysha Gene Therapies, Inc."},"Symbol":{"label":"Symbol","value":"TSHA"},"Address":{"label":"Address","value":"3000 PEGASUS PARK DRIVE,SUITE 1430, DALLAS, Texas, 75247, United States"},"Phone":{"label":"Phone","value":"+1 214 612-0000"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. It is advancing a deep and sustainable product portfolio of 18 gene therapy product candidates, with exclusive options to acquire four additional development programs. Its product candidates include TSHA-101, TSHA-118, TSHA-102, TSHA-103, and TSHA-104."},"CompanyUrl":{"label":"Company Url","value":"https://www.tayshagtx.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Fred Porter","title":"Chief of Staff & Technical Operations Officer"},{"name":"Jim Rouse","title":"Chief Information Officer"},{"name":"Sean P. Nolan","title":"Chairman & Chief Executive Officer"},{"name":"Sukumar Nagendran","title":"President, Director, Head-Research & Development"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}